205 related articles for article (PubMed ID: 28424071)
1. Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT).
Ubink I; Bloemendal HJ; Elias SG; Brink MA; Schwartz MP; Holierhoek YCW; Verheijen PM; Boerman AW; Mathijssen RHJ; de Leng WWJ; de Weger RA; van Grevenstein WMU; Koopman M; Lolkema MP; Kranenburg O; Borel Rinkes IHM
BMC Cancer; 2017 Apr; 17(1):282. PubMed ID: 28424071
[TBL] [Abstract][Full Text] [Related]
2. Consensus molecular subtype 4 (CMS4)-targeted therapy in primary colon cancer: A proof-of-concept study.
Peters NA; Constantinides A; Ubink I; van Kuik J; Bloemendal HJ; van Dodewaard JM; Brink MA; Schwartz TP; Lolkema MPJK; Lacle MM; Moons LM; Geesing J; van Grevenstein WMU; Roodhart JML; Koopman M; Elias SG; Borel Rinkes IHM; Kranenburg O
Front Oncol; 2022; 12():969855. PubMed ID: 36147916
[TBL] [Abstract][Full Text] [Related]
3. A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type Colon Cancer Reveals Intratumor Subtype Heterogeneity.
Ubink I; Elias SG; Moelans CB; Laclé MM; van Grevenstein WMU; van Diest PJ; Borel Rinkes IHM; Kranenburg O
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376187
[TBL] [Abstract][Full Text] [Related]
4. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
Farag S; Somaiah N; Choi H; Heeres B; Wang WL; van Boven H; Nederlof P; Benjamin R; van der Graaf W; Grunhagen D; Boonstra PA; Reyners AK; Gelderblom H; Steeghs N
Eur J Cancer; 2017 May; 76():76-83. PubMed ID: 28284172
[TBL] [Abstract][Full Text] [Related]
7. Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours.
Dretzke J; Round J; Connock M; Tubeuf S; Pennant M; Fry-Smith A; Hulme C; McCabe C; Meads C
Health Technol Assess; 2010 Oct; 14(Suppl. 2):63-70. PubMed ID: 21047493
[TBL] [Abstract][Full Text] [Related]
8. Imatinib Inhibits the Renewal and Tumorigenicity of CT-26 Colon Cancer Cells after Cytoreductive Treatment with Doxorubicin.
Przybyszewska M; Miłoszewska J; Kotlarz A; Swoboda P; Pyśniak K; Szczepek W; Kaczmarek Ł; Markowicz S
Arch Immunol Ther Exp (Warsz); 2017 Feb; 65(1):51-67. PubMed ID: 26956644
[TBL] [Abstract][Full Text] [Related]
9. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
10. Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine.
Mouillet-Richard S; Cazelles A; Sroussi M; Gallois C; Taieb J; Laurent-Puig P
Clin Cancer Res; 2024 Jun; 30(11):2351-2358. PubMed ID: 38564259
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
12. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Medinger M; Steinbild S; Mross K
Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by
Strating E; Wassenaar E; Verhagen M; Rauwerdink P; van Schelven S; de Hingh I; Rinkes IB; Boerma D; Witkamp A; Lacle M; Fodde R; Volckmann R; Koster J; Stedingk K; Giesel F; de Roos R; Poot A; Bol G; Lam M; Elias S; Kranenburg O
Br J Cancer; 2022 Jul; 127(1):145-155. PubMed ID: 35296803
[TBL] [Abstract][Full Text] [Related]
14. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
15. Tumour budding is associated with the mesenchymal colon cancer subtype and RAS/RAF mutations: a study of 1320 colorectal cancers with Consensus Molecular Subgroup (CMS) data.
Trinh A; Lädrach C; Dawson HE; Ten Hoorn S; Kuppen PJK; Reimers MS; Koopman M; Punt CJA; Lugli A; Vermeulen L; Zlobec I
Br J Cancer; 2018 Nov; 119(10):1244-1251. PubMed ID: 30385823
[TBL] [Abstract][Full Text] [Related]
16. [Gastrointestinal stromal tumour (GIST): current standards in multimodal management].
Reichardt P; Reichardt A
Zentralbl Chir; 2011 Aug; 136(4):359-63. PubMed ID: 21863513
[TBL] [Abstract][Full Text] [Related]
17. Patients with mesenchymal tumours and high
Salvucci M; Crawford N; Stott K; Bullman S; Longley DB; Prehn JHM
Gut; 2022 Aug; 71(8):1600-1612. PubMed ID: 34497144
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
19. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Kantarjian HM; Talpaz M
Semin Oncol; 2001 Oct; 28(5 Suppl 17):9-18. PubMed ID: 11740802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
